FCF YoY
+10.83%
OCF YoY
+5.74%
Capex YoY
-9.03%
FCF Conversion Δ
+3.6 pp
Free cash flow bridge for Abbott Laboratories (ABT) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $721M
FCF bridge breakdown for Abbott Laboratories (ABT) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | $6.66B | — |
| Operating Cash Flow | $514M | +71.3% |
| Capital Expenditure | $207M | +28.7% |
| Free Cash Flow | $7.38B | — |
- Prior Free Cash Flow$6.66B
- Operating Cash Flow$514M
- Capital Expenditure$207M
- Free Cash Flow$7.38B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
- Buybacks0.44% TTM
- Dividend Profile2.47% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History9 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.